We are live on ! Find out more
ADVM

Adverum Biotechnologies
ADVM

Delisted

ADVM was delisted on the 8th of December, 2025.

Back to rankings

58 hedge funds and large institutions have $49.5M invested in Adverum Biotechnologies in 2017 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 17 increasing their positions, 15 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

52% more capital invested

Capital invested by funds: $32.5M → $49.5M (+$16.9M)

13% more repeat investments, than reductions

Existing positions increased: 17 | Existing positions reduced: 15

0.1% more ownership

Funds ownership: 3.04% → 3.14% (+0.1%)

8% less funds holding

Funds holding: 63 → 58 (-5)

33% less first-time investments, than exits

New positions opened: 8 | Existing positions closed: 12

100% less call options, than puts

Call options by funds: $0 | Put options by funds: $19K

Holders
58
Holders Change
-5
Holders Change %
-7.94%
% of All Funds
1.45%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
8
Increased
17
Reduced
15
Closed
12
Calls
–
Puts
$19K
Net Calls
-$19K
Net Calls Change
-$6K

Top Buyers

Rank Fund Capital Flow
1
SC
Sessa Capital
New York
+$1.3M
2
Renaissance Technologies
Renaissance Technologies
New York
+$1.16M
3
MP
Mangrove Partners
Connecticut
+$1.15M
4
Vanguard Group
Vanguard Group
Pennsylvania
+$988K
5
TCM
Tekla Capital Management
Massachusetts
+$833K

Top Sellers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
-$947K
2
NI
Numeric Investors
Massachusetts
-$804K
3
Fidelity Investments
Fidelity Investments
Massachusetts
-$654K
4
AIC
AWM Investment Company
New York
-$500K
5
Goldman Sachs
Goldman Sachs
New York
-$420K
Name Holding Trade Value Shares
Change 		Change in
Stake
UBS Group
51
UBS Group
Switzerland
$6K -$1.78K -64 -26%
MAM
52
Meeder Asset Management
Ohio
$6K – – –
Morgan Stanley
53
Morgan Stanley
New York
$6K +$1.61K +58 +52%
Federated Hermes
54
Federated Hermes
Pennsylvania
$5K +$3.58K +129 New
Manulife (Manufacturers Life Insurance)
55
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$1K -$1.53K -55 -57%
EWM
56
Edge Wealth Management
New York
$1K – – –
JCM
57
Jacobi Capital Management
Pennsylvania
$1K – – –
BNP Paribas Financial Markets
58
BNP Paribas Financial Markets
France
$22 – – –
AIC
59
AWM Investment Company
New York
– -$500K -20,000 Closed
Goldman Sachs
60
Goldman Sachs
New York
– -$420K -16,803 Closed
PP
61
Paloma Partners
Connecticut
– -$413K -16,510 Closed
SM
62
Sabby Management
Florida
– -$275K -11,000 Closed
LP
63
LMR Partners
United Kingdom
– -$244K -9,778 Closed
Susquehanna International Group
64
Susquehanna International Group
Pennsylvania
– -$162K -6,471 Closed
GGHC
65
Gilder Gagnon Howe & Co
New York
– -$111K -4,456 Closed
ARTA
66
A.R.T. Advisors
New York
– -$84K -3,366 Closed
PPA
67
Parametric Portfolio Associates
Washington
– -$39K -1,571 Closed
Bank of America
68
Bank of America
North Carolina
– -$19K -755 Closed
PCM
69
Prelude Capital Management
New York
– -$1K -40 Closed
Wells Fargo
70
Wells Fargo
California
– -$1K -20 Closed
1 2
3

ADVM Hedge Fund Activity: Q3 2017 in Review

58 of the 4,012 institutional investors tracked by Wall St. Rank reported a position in Adverum Biotechnologies (ADVM) for Q3 2017, worth a combined $49.5M — up 52% from $32.5M a quarter earlier.

Sellers outnumbered buyers: 12 funds closed out of ADVM and 8 opened new positions — a net loss of 4 holders — while 15 trimmed existing stakes and 17 added.

The largest buyer was Sessa Capital, adding an estimated $1.3M. The largest seller was Millennium Management, cutting an estimated $947K.

  • 58 institutional investors held Adverum Biotechnologies (ADVM) as of Q3 2017, down from 63 in Q2 2017.
  • Funds reported $49.5M of Adverum Biotechnologies stock for Q3 2017, up 52% quarter-over-quarter.
  • 8 funds opened new Adverum Biotechnologies positions in Q3 2017 and 12 closed out, a net change of -4 holders.
  • The largest Adverum Biotechnologies buyer in Q3 2017 was Sessa Capital, an estimated $1.3M added.
  • The largest Adverum Biotechnologies seller in Q3 2017 was Millennium Management, an estimated $947K sold.

Based on aggregated 13F filings for Q3 2017.